Predicting circulating biomarker response and its impact on the survival of advanced melanoma patients treated with adjuvant therapy
Advanced melanoma remains a disease with poor prognosis. Several serologic markers have been investigated to help monitoring and prognostication, but to date only lactate dehydrogenase (LDH) has been validated as a standard prognostic factor biomarker for this disease by the American Joint Committee...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198615/ https://www.ncbi.nlm.nih.gov/pubmed/32366871 http://dx.doi.org/10.1038/s41598-020-63441-6 |